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ORIGINAL ARTICLE
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Background: The FAS and FASL system plays a key role in regulating apoptotic cell death and corruption
of this signalling pathway has been shown to participate in immune escape and tumorigenesis. There is
reduced expression of FAS but elevated expression of FASL in many types of human cancers including lung
cancer. We recently reported an association between functional polymorphisms in FAS (21377GRA)
and FASL (2844TRC) and risk of oesophageal cancer.
Objective: To examine the contribution of these polymorphisms to risk of developing lung cancer.
Methods: Genotypes of 1000 lung cancer patients and 1270 controls were analysed by PCR based
restriction fragment length polymorphism. Associations with risk of lung cancer were estimated by logistic
regression.
Results: Compared with non-carriers, there was a 1.6 fold excess risk of developing lung cancer for
carriers of the FAS 21377AA genotype (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.21 to 2.10;
p = 0.001), and 1.8 fold excess risk (OR 1.79, 95% CI 1.26 to 2.52; p = 0.001) for carriers of FASL
2844CC. Gene–gene interaction of FAS and FASL polymorphisms increased risk of lung cancer in a
multiplicative manner (OR for the carriers of both FAS 21377AA and FASL 2844CC genotypes 4.18,
95% CI 2.83 to 6.18). Gene–environment interaction of FAS or FASL polymorphism and smoking
associated with increased risk of lung cancer was also found.
Conclusion: These results are consistent with our initial findings in oesophageal cancer and further support
the hypothesis that the FAS and FASL triggered apoptosis pathway plays an important role in human
carcinogenesis.
A
poptosis is involved in a variety of physiological
functions, such as regulating cell numbers and
eliminating unwanted or potentially dangerous cells
during the development of organisms, as well as in some
pathological processes, including immune disorders and
tumour development.1 2 One of the most important advances
in basic cancer research in past decades was the realisation
that apoptosis and the genes that control it have a profound
effect on the malignant phenotype. It has been shown that
some tumour cells successfully develop either by having the
ability to resist apoptotic stimuli or by inducing apoptosis of
tumour specific lymphocytes.3–5
FAS, a cell surface receptor, plays a crucial role in apoptotic
signalling in many cell types.6 7 This receptor interacts with
its natural ligand (FASL), a member of the tumour necrosis
factor superfamily, to initiates the death signal cascade,
which results in apoptotic cell death.4 7 8 FAS receptor is
widely expressed in a variety of tissues, whereas the
expression of FASL is restricted to the cells within immune
system, such as activated T cells and natural killer cells, and
the cells within immune privileged areas, such as the eye and
reproductive organs. However, reduced expression of FAS
and/or increased expression of FASL have been detected in
many types of human cancer, including lung cancer, and
appears to be a feature of the malignant phenotype,9–14
suggesting that the FAS/FASL system may play an important
role in cancer formation. There is strong evidence demon-
strating that decreased expression of FAS may protect
transformed cells from elimination by anti-tumour immune
responses, but heightened expression of FASL may increase
the ability of tumour cells to counterattack the immune
system by killing FAS sensitive lymphocytes and therefore
contribute to cancer development.4 10 14–17 Furthermore, func-
tional germline and somatic mutations in the FAS gene and
perhaps also in the FASL gene that impair apoptotic signal
transduction are associated with susceptibility to cancers,
including lung cancer.18–22
Single nucleotide polymorphisms have been identified in
the promoter region of the FAS and FASL genes.23–25 It has
been shown that a GRA transition at position 21377 and an
ARG transition at position 2670 in the promoter region of
FAS destroy stimulatory protein (Sp) 1 and signal transducer
and activator of transcription (STAT) 1 protein binding
element, respectively, and thus diminish promoter activity
and decrease FAS expression.23 24 In FASL, a TRC transition at
position 2844 in the promoter region has been reported to be
located in a binding motif for another transcription factor,
CAAT/enhancer binding protein b.25 Higher basal expression
of FASL is significantly associated with the FASL 2844C
allele compared with the 2844T allele.25 Because of the role
that FAS and FASL play in carcinogenesis and cancer
progression and because of their aberrant expression in
various types of cancer, we hypothesised that these func-
tional polymorphisms in FAS and FASL might have an impact
on cancer susceptibility attributable to the reduced expres-
sion of FAS and/or the increased expression of FASL.
Recently, we examined this hypothesis in oesophageal
squamous cell carcinoma (SCC) and found that these
polymorphisms in the promoter region of FAS and FASL
were associated with the development of oesophageal SCC in
a Chinese population.26 In addition, the effect of FAS and
FASL polymorphisms on risk of oesophageal SCC displayed a
Abbreviations: FASL, FAS ligand; PCR-RFLP, polymerase chain
reaction based restriction fragment length polymorphism; SCC,
squamous cell carcinoma; Sp, stimulatory protein; STAT, signal
transducer and activator of transcription
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multiplicative gene–gene interaction and appeared to corre-
late with tobacco smoking.26
Lung cancer is one of the most common cancers in many
countries. During the past two decades, the rates of incidence
and mortality of lung cancer in China have been increasing
significantly and constantly.27 Tobacco smoking is the major
cause of lung cancer, and the increasing incidence of smoking
has been suggested to be the major factor underlying the
increasing trend in lung cancer mortality in China.27–29 However,
the smoking habit among Chinese women is rare; nationwide
surveys showed that the prevalence of smoking among women
aged 15–24 years was 0.5% both in 1984 and in 1996.29 Despite
this, the mortality rates from lung cancer in Chinese women are
relatively high,30 which has emphasised the impact of another
aetiological factor, such as exposure to environmental tobacco
smoke and indoor air pollution derived from Chinese style
cooking and/or coal burning.31 32 However, although risk of lung
cancer is conclusively associated with tobacco smoke and
perhaps indoor air pollution, only a proportion of exposed
individuals develop the cancer in their life span, suggesting that
theremay be important genetic basis rendering such individuals
more susceptible to the disease.
This paper describes a case–control study that aimed to
examine the contribution of aforementioned FAS and FASL
polymorphisms to the risk of lung cancer. We genotyped 1000
patients with primary lung cancer and 1270 healthy controls,
and found that the FAS and FASL polymorphisms are
associated with the risk of lung cancer.
MATERIALS AND METHODS
Study subjects
This study consisted of 1000 patients with primary lung
cancer and 1270 healthy controls. All subjects were unrelated
Han Chinese and residents in Beijing and the surrounding
regions. Characteristics of the study subjects have been
described previously.33 All incident patients, who were
histopathologically confirmed and previously untreated (by
radiotherapy or chemotherapy), were consecutively recruited
from 20 January 1997 to 20 June 2002 at the Cancer Hospital,
Chinese Academy of Medical Sciences. Of the 1000 patients,
26 were newly recruited because DNA samples from 26
patients used in the previous study were no longer available.
The exclusion criteria included previous cancer, metastasised
cancer from other organs, previous radiotherapy, or che-
motherapy. Controls were randomly selected from a pool of
cancer free subjects recruited from a nutritional survey
conducted in the same region during the same period as
case collection. The selection criteria for controls included no
individual history of cancer, and sex and age (5 years)
matching to patients. In this study, we also selected 270 more
controls from the same database matched to cases as
described above, for a total of 1270 controls, to increase
statistical power. Smokers were considered current smokers
if they smoked up to 1 year before the date of cancer
diagnosis or the date of the interview for controls. Non-
smokers were defined as subjects who had smoked ,10
cigarettes in their lifetime. Information was collected on the
number of cigarettes smoked per day, the age at which the
subjects started smoking, and the age at which ex-smokers
stopped smoking. At recruitment, written informed consent
was obtained from each subject, and each participant was
then interviewed to collect detailed information on demo-
graphic characteristics and lifetime history of tobacco use.
This study was approved by the institutional review board.
Polymorphism analysis
Genomic DNA from controls and most of the patients was
extracted from the leukocyte pellet obtained from buffy coat
in each blood sample, obtained by centrifugation of 2 ml
whole blood. Approximately 25% of the DNA samples from
patients was isolated from surgically resected normal tissues
adjacent to the tumour of lung cancer patients. All patients
and controls were genotyped using PCR based restriction
fragment length polymorphism (PCR-RFLP) methods as
described previously.26 A 10% masked, random sample of
subjects was tested twice by different researchers, and the
results were concordant for all of the masked duplicate sets.
Because the FAS 21377G/A and 2670G/A polymorphisms
are in almost complete linkage disequilibrium in our study
population,26 only the21377G/A polymorphism was analysed
for FAS in this study. The PCR primers for amplification of the
FAS promoter region containing 21377G/A were 59-
TGTGTGCACAAGGCTGGCGC and 59-TGCATCTGTCACTGC
ACTTACCACCA, which produce a 122 bp fragment. In
order to induce a restriction endonuclease site, we changed
the 39 end of the reverse primer from CAC to CGC, which
created a BstuI cutting site. For amplification of the FASL
promoter region containing 2844T/C site, we used the
primer pair of 59-CAGCTACTCGGAGGCCAAG and 59-
GCTCTGAGGGGAGAGACCAT, which generates a 401 bp
fragment. Amplification of these two DNA fragments was
accomplished separately under the same conditions, in a
25 ml reaction mixture consisting of ,100 ng template DNA,
0.5 mmol/l each primer, 0.2 mmol/l dNTP, 2.0 mmol/l MgCl2,
and 1.0 U of Taq DNA polymerase with 16 reaction buffer
(Promega, Madison, WI, USA). The reaction was carried out
in the following conditions: an initial melting step of
2 minutes at 94 C˚, followed by 35 cycles of 30 seconds at
94 C˚, 30 seconds at 62 C˚, and 45 seconds at 72 C˚, and a final
elongation step of 7 minutes at 72 C˚.
The restriction enzymes BstuI and BsrDI (New England
Biolabs Inc., Beverly, MA, USA) were used to distinguish the
FAS 21377G/A and FASL 2844T/C polymorphisms, respec-
tively. The restriction products were separated on 2.5%
agarose gel with ethidium bromide. The RFLPs of the two
polymorphisms were readily discerned. After digestion with
BstuI, the FAS 21377G allele generated 104 bp and 18 bp
fragments whereas the variant 21377A allele generated a
single 122 bp fragment. The FASL 2844C allele had a BsrDI
restriction site that resulted in two bands (233 bp and
168 bp), and the 2844T allele lacked the BsrDI restriction
site, producing a single 401 bp band.
Statistical analysis
Pearson’s x2 test was used to examine differences in
demographic variables, smoking, and distributions of FAS
21377G/A and FASL 2844T/C between patients and controls.
The associations between the polymorphisms and risk of
developing lung cancer were estimated by odds ratios (ORs)
and their 95% confidence intervals (CIs), which were
calculated by unconditional logistic regression. For smokers,
pack year value was calculated to indicate cumulative
cigarette dose (pack years= (cigarettes/day 420)6 years of
smoking). Light and heavy smokers were categorised by
median pack year value of the controls—that is, (20 pack
years and .20 pack years. Because only 22 patients and 64
controls were ex-smokers, they were combined with current
smokers for analysis. All ORs were all adjusted for age, sex,
and smoking status or pack years, as appropriate. All
statistical tests were two sided tests. We tested the null
hypotheses of additive and multiplicative gene–gene and
gene–smoking interactions, and evaluated the departures
from additive and multiplicative interaction models34 by
including main effect variables and their product terms in the
logistic regression model. All analyses were performed using
Statistical Analysis System software (version 6.12; SAS
Institute, Cary, NC, USA).
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RESULTS
Table 1 shows distributions of select characteristics of study
subjects by case–control status. The patients and controls
appeared to be adequately matched for sex and age. The
proportions of men and women were almost the same among
patients and controls (73.5% and 26.5% v 72.3% and 27.7%;
p=0.535). The age distribution of patients was not sig-
nificantly different from that of controls (p=0.643). As
expected, smokers were over-represented in patients com-
pared with controls (65.5% v 50.8%; p,0.0001). Furthermore,
70.8% smokers in patients smoked .20 pack years that was
significantly higher than that in controls (52.7%; p,0.0001).
Of the 1000 patients with lung cancer, 448 (44.8%) were SCC,
297 (29.7%) were adenocarcinoma, and 255 (25.5%) were
other types of lung cancer, including undifferentiated cancer
(n=90), bronchioalveolar carcinoma (n=90), small cell
carcinoma (n=24), and mixed cell carcinoma (n=51).
The genotyping results are shown in table 2. The allelic
frequencies for FAS 21377A and FASL 2844C were 0.339 and
0.694 in controls compared with 0.371 and 0.774 in patients,
respectively. The observed genotype frequencies of FAS
21377G/A and FASL 2844T/C polymorphism among controls
and patients conformed to the Hardy-Weinberg equilibrium
(p.0.05; respectively). Frequencies for the FAS 21377GG,
GA, and AA genotypes in patients differed significantly from
those in controls (x2=14.09; p=0.001), with the frequency
of homozygous AA genotype being significantly higher in
patients than that in controls (15.4% v 10.2%; p=0.001). The
difference in genotypic frequencies at the FASL 2844T/C
site—that is, 2844TT, TC, and CC, between patients and
controls was also statistically significant (x2=43.31;
p,0.0001), with the homozygous CC genotype being more
prevalent among patients than that among controls (61.2% v
47.3%; p,0.0001). Multivariate logistic regression analyses
showed that the FAS 21377AA genotype carriers had a
1.6 fold excess risk for developing lung cancer compared with
the FAS 21377GG genotype carriers (adjusted OR 1.59, 95%
CI 1.21 to 2.10). Similarly, the FASL 2844CC genotype
carriers also had increased risk for the cancer compared with
the FASL2844TT genotype carriers (adjusted OR 1.79, 95% CI
1.26 to 2.52). However, both heterozygous genotypes for FAS
and FASL polymorphisms were not associated with elevated
risk of the cancer, suggesting a possible recessive effect of the
polymorphisms in these two genes. Age, sex, and smoking
status had little effect on the risk of lung cancer associated
with the FAS or FASL genotypes (table 2).
Because FAS and FASL are receptor/ligand system and work
together in apoptotic cell death, we examined whether there
was a statistical interaction between the polymorphism in
FAS and in FASL that was associated with the risk of lung
cancer. As the heterozygous genotypes of both FAS and FASL
genes were not associated with risk of lung cancer, these
genotypes were incorporated into the corresponding wildtype
genotype (FAS 21377GG or FASL 2844TT) as the reference
group for analysis (table 3). It was found that patients
carrying the FASL2844CC genotype were more likely to carry
FAS 21377AA than were controls (10.0% v 3.5%; p,0.0001).
The adjusted OR for the presence of one FAS 21377AA
genotype or one FASL 2844CC genotype was 1.11 (95% CI
0.76 to 1.62) or 1.64 (95% CI 1.36 to 1.97), respectively,
compared with the lack of such a genotype. However, the
adjusted OR for subjects carrying both FASL 2844CC and FAS
21377AA genotypes increased to 4.18 (95% CI 2.83 to 6.18;
p,0.001, test for homogeneity) compared with those who
lacked both genotypes. These results indicate that there is a
more than multiplicative interaction between the FASL
2844CC and FAS 21377AA genotype that is associated with
elevated risk of developing lung cancer.34
Tobacco smoking is a well known environmental aetiolo-
gical factor for lung cancer and has been shown to influence
FAS/FASL expression;35 36 we therefore investigated gene-
environment interaction between the polymorphisms and
smoking (table 4). We observed that the FAS 21377AA
genotype compared with the GG or GA genotype was not
associated with increased risk of lung cancer among non-
smokers (OR 1.23, 95% CI 0.83 to 1.81; p=0.306). However,
this variant genotype was significantly associated with a
twofold increased risk of lung cancer in smokers (OR 2.12,
95% CI 1.46 to 3.07; p,0.001). When smoking was
additionally stratified by pack year value, the increased risk
of lung cancer associated with the 21377AA genotype
appeared to be more pronounced in light (OR 2.92, 95%
CI=1.51 to 5.66) than in heavy smokers (OR 1.84, 95% CI
1.18 to 2.89). In contrast, although the FASL 2844CC
genotype was significantly associated with increased risk of
lung cancer both in smokers and non-smokers compared
with the TT or TC genotype, the risk seemed to be higher in
heavy (OR 1.96, 95% CI 1.45 to 2.64) than in light smokers
(OR 1.37, 95% CI 0.94 to 1.98).
We also compared the risk of lung cancer associated with
the FAS and FASL polymorphisms among different sub-
types—that is, SCC, adenocarcinoma, and other histological
types of lung cancer. No statistically significant differences in
terms of risk associated with the FAS 21377AA genotype or
FASL 2844CC genotype were found among histological types
of lung cancer and the increased risk was consistently
observed in all subtypes of the cancer (table 4).
DISCUSSION
In the previous study, we reported that the FAS 21377G/A or
2670A/G and FASL 2844T/C polymorphisms were signifi-
cantly associated with increased risk of oesophageal SCC in a
Chinese population.26 Because aberrant expression of FAS
and/or FASL has been detected in lung cancer,12–14 and
germline and somatic mutations in the FAS and FASL genes
are associated with a high risk of cancers,18–22 we investigated
whether functional polymorphisms in FAS and FASL could
affect the risk of lung cancer development. We analysed 1000
patients with lung cancer and 1270 healthy controls, and
found that the FAS 21377AA and FASL 2844CC genotypes
were statistically significantly associated with increased risk
Table 1 Distributions of select characteristics by case–
control status
Variable
Patients
(n =1000)
Controls
(n= 1270)
p value*n % n (%)
Sex 0.535
Male 723 72.3 933 73.5
Female 277 27.7 337 26.5
Age (years) 0.643
(50 248 24.8 327 25.8
51–60 330 33.0 440 34.6
61–70 320 32.0 386 30.4
.70 102 10.2 117 9.2
Smoking status ,0.0001
Nonsmoker 350 34.5 625 49.2
Smoker 650 65.5 645 50.8
Smoking level
(pack years)
,0.0001
(20 190 29.2 305 47.3
.20 460 70.8 340 52.7
Histological type
SCC 448 44.8
Adenocarcinoma 297 29.7
Other 255 25.5
*Two sided x2 test. Includes 90 undifferentiated cancers, 90
bronchioalveolar carcinomas, 24 small cell carcinomas (SCC), and 51
mixed cell carcinomas.
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of lung cancer. In addition, the association between these
two polymorphisms and the risk of lung cancer displayed a
multiplicative gene–gene interaction, which rendered the
subjects having both FAS 21377AA and FASL 2844CC
genotypes at much higher risk for developing lung cancer.
Moreover, we observed a statistically significant interaction
between the polymorphisms and tobacco smoking. Another
interesting finding in the present study was that the
increased risk associated with FAS and FASL polymorphisms
was similar in different subtypes of lung cancers, suggesting
that these polymorphisms might be general risk factors for
common cancers. These results are consistent with our
previous findings from oesophageal SCC,26 and further
support the hypothesis that the FAS and FASL triggered
apoptosis pathway plays an important role in human
carcinogenesis.
Previous studies have shown that the investigated FAS
21377G/A and FASL 2844T/C polymorphisms are function-
ally significant. The FAS 21377GRA transition is located
within an Sp1 transcriptional factor binding site in the
promoter region of FAS.23 24 Because the 21377A allele has a
significantly reduced ability to bind Sp1, an important and
ubiquitously expressed transcriptional activator,37 decreased
FAS expression associated with the 21377AA genotype is
expected.23 24 The FASL 2844TRC mutation is also located in
the promoter region of FASL, and the 2844C allele has been
shown to have significantly higher promoter activity and
basal FASL expression compared with the 2844T allele.25
These findings strongly support our molecular epidemiologi-
cal observation that the FAS 21377AA and/or FASL 2844CC
genotype is associated with significantly increased risk of
lung cancer. Because the FAS/FASL system plays an
important role in apoptosis and cancer development, it may
be expected that individuals who carry the FAS 21377AA
and/or FASL 2844CC genotype, thus having decreased
expression of FAS and/or increased expression of FASL over
a lifetime, are at high risk of developing lung cancer.
Supporting evidence also comes from association studies by
other investigators reporting that the FAS polymorphisms are
associated with increased risk of lymphoproliferative diseases
and some cancers. For instance, it has been shown that
increased risk for acute myeloid leukaemia, cervical cancer,
and oesophageal cancer is associated with the FAS 21377AA
and/or 2670GG genotype.24 26 38 To date, only one study has
been published reporting the association between the FAS
polymorphism at the 2670A/G site and the risk of lung
cancer.39 Although the FAS 2670A/G polymorphism was not
an independent risk factor for lung cancer in their study,
which is most likely due to very limited statistical power
(only 68 patients and 74 controls), it appeared to modulate
the risk associated with low apoptotic capacity, with the
2670G allele being a risk allele. These data are generally in
agreement with our results in this study of a Chinese
population, where the FAS 2670A/G polymorphism was
almost completely linked with the 21377G/A polymorphism.
Although no study except our previous one26 has reported
whether the FASL polymorphism is associated with the risk of
cancer, the FASL 2844CC genotype has been associated with
the risk of systemic lupus erythematosus,25 an autoimmune
disease characterised by accelerated FAS mediated apoptosis
of lymphocytes and monocytes. Therefore, these data
strongly support our hypothesis that functional polymorph-
isms in FAS and/or FASL may contribute to susceptibility to
cancer.
We also observed a more than multiplicative gene–gene
interaction between FAS and FASL polymorphisms in
increasing the risk of lung cancer, suggesting that these
two polymorphisms are likely to be active in the same causal
pathway. This result is fairly consistent with our previous
study on oesophageal SCC.26 The statistical interaction
between FAS and FASL polymorphisms is biologically
plausible because these two molecules are a receptor ligand
system, and apoptotic cell death needs both normal FAS and
normal FASL.40 Therefore, if a cell carries functional
polymorphisms in both genes that have an effect on their
level of expression, then a greater than additive effect is to be
expected. In the development of lung cancer, transformed
cells carrying the FASL 2844CC genotype that express high
level of FASL may create an immunoprivileged site by killing
cytotoxic immune cells and thus escaping host immunosur-
veillance; on the other hand, reduced expression of FAS due
to the FAS 21377AA genotype may assist the transformed
cells to evade FAS mediated cell death. As a result, subjects
carrying both FAS 21377AA and FASL 2844CC could be at
Table 2 Genotypic and allelic frequencies of FAS and FASL in patients and controls and
their associations with the risk of lung cancer
Genotype
Controls
(n =1270)n (%)
Patients
(n=1000)n (%) Crude OR* (95% CI)
Adjusted OR
(95% CI)
FAS 21377G/A
GG 539 (42.5) 413 (41.3) 1.00 (reference) 1.00 (reference)
GA 601 (47.3) 433 (43.3) 0.94 (0.78 to 1.13) 0.94 (0.78 to 1.14)
AA 130 (10.2) 154 (15.4) 1.55 (1.17 to 2.04) 1.59 (1.21 to 2.10)
A allele frequency 0.339 0.371
FASL 2844T/C
TT 109 (8.6) 64 (6.4) 1.00 (reference) 1.00 (reference)
TC 560 (44.1) 324 (32.4) 0.99 (0.69 to 1.40) 1.00 (0.71 to 1.42)
CC 601 (47.3) 612 (61.2) 1.73 (1.23 to 2.44) 1.79 (1.26 to 2.52)
C allele frequency 0.694 0.774
*Data were calculated by unconditional logistic regression, and adjusted for sex, age, smoking status, and other
genotype where appropriate. OR, odds ratio; CI, confidence interval.
Table 3 Risk of lung cancer associated with FAS
genotypes by FASL genotypes among patients and
controls
Genotypes
Patients,
n (%)
Controls,
n (%) OR* (95% CI)
FASL
2844
FAS
21377
TT+TC GG+GA 334 (33.4) 584 (46.0) 1.00
(referent)
TT+TC AA 54 (5.4) 85 (6.7) 1.11
(0.76 to 1.62)
CC GG+GA 512 (51.2) 556 (43.8) 1.64
(1.36 to 1.97)
CC AA 100 (10.0) 45 (3.5) 4.18
(2.83 to 6.18)
*Data were calculated by unconditional logistic regression, adjusting for
sex, age, and smoking status. OR, odds ratio; CI, confidence interval.
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higher risk for developing lung cancer than those carrying
either the FAS 21377AA or FASL 2844CC alone. This
speculation is consistent with the findings from direct studies
on FAS/FASL expression in certain cancers, including lung
cancer, showing frequent loss of FAS expression and gain of
FASL expression in cancer cells.10–12 41 42
A statistical interaction between FAS and FASL polymorph-
isms and tobacco smoking was also evident in the present
study. The FAS 21377AA genotype modulated the risk of
lung cancer among smokers but not among non-smokers,
suggesting a gene–environment interaction. However, among
smokers, the increased risk of lung cancer associated with the
FAS 21377AA genotype was higher in light than in heavy
(.20 pack years in this study) smokers. This finding may
reflect the fact that the genetic effect can be overwhelmed by
the environmental effect. Tobacco smoking is an established
causal factor for lung cancer; therefore, this interaction is
biologically plausible. A higher risk of lung cancer among
smokers who carried the FAS 21377AA genotype may be
attributed to many transformed or pre-invasive lung cells
caused by tobacco carcinogens, which in turn increases the
possibility that, owing to low FAS expression, one of these
cells will evade immunosurveillance to become carcinogenic.
For the FASL polymorphism, however, a significantly
increased risk of lung cancer was observed in both smokers
and non-smokers, and the risk among smokers was more
pronounced in heavy than in light smokers. It is also rational
to speculate that the presence of the FASL 2844CC genotype,
which is associated with increased level of FASL expression,
will help transformed or preinvasive lung cells counterattack
against anti-tumour immune cells and thus contribute to
tumour immune escape. Moreover, because tobacco smoking
can induce FASL expression,35 36 another hypothesis for the
interaction is that, in addition to higher constitutive
expression resulting from the FASL 2844T/C polymorphism,
smoking may induce a higher level of FASL expression from
the FASL 2844C allele than from the FASL 2844T allele. As a
result, smoking and carrying the FASL 2844CC genotype
increase susceptibility to lung cancer. A higher risk of lung
cancer associated with the FASL 2844CC genotype in non-
smokers than in light smokers who smoked less than 20 pack
years may be ascribed to the exposure of these non-smokers
to high level of environmental smoke, because smoking is
very prevalent and unlimited in public places in China. The
pattern of this interaction between FAS and FASL polymorph-
isms and smoking in lung cancer is very similar to that
observed in our previous study on oesophageal SCC,
suggesting that this gene–environment interaction may have
important implications in smoking related human cancer
development.
Our patients may not be representative of total lung cancer
patients in the study area because they were recruited from
only one hospital. However, because we used incident
patients, and recruited a large number of subjects, our results
are unlikely to be attributable to selection bias. In addition,
the genotypic frequencies of FASL 2844T/C and FAS 21377G/
A polymorphisms observed in 1270 controls in this study are
identical to those reported previously,26 further validating our
results. Nevertheless, it is important to carry out multicentre
case–control studies and/or population based prospective
studies in different ethnic populations for comparison.
In conclusion, this case–control study with a large sample
size provides the first evidence that functional FAS and FASL
polymorphisms are associated with the risk of lung cancer.
This association is especially noteworthy in tobacco smokers
and displays a multiplicative gene–gene interaction between
FAS and FASL polymorphisms. These results are consistent
with our initial findings in the oesophageal SCC study,
further supporting the hypothesis that FAS and FASL
triggered apoptosis pathway plays an important role in
human carcinogenesis.
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